AFEDITAB CR Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Afeditab Cr, and what generic alternatives are available?
Afeditab Cr is a drug marketed by Watson Labs and Watson Labs Teva and is included in two NDAs.
The generic ingredient in AFEDITAB CR is nifedipine. There are thirty-nine drug master file entries for this compound. Thirty-six suppliers are listed for this compound. Additional details are available on the nifedipine profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Afeditab Cr
A generic version of AFEDITAB CR was approved as nifedipine by ACTAVIS ELIZABETH on January 8th, 1991.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for AFEDITAB CR?
- What are the global sales for AFEDITAB CR?
- What is Average Wholesale Price for AFEDITAB CR?
Summary for AFEDITAB CR
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 165 |
| Patent Applications: | 3,779 |
| Drug Prices: | Drug price information for AFEDITAB CR |
| DailyMed Link: | AFEDITAB CR at DailyMed |
See drug prices for AFEDITAB CR
US Patents and Regulatory Information for AFEDITAB CR
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Watson Labs | AFEDITAB CR | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 075659-001 | Oct 26, 2001 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Watson Labs Teva | AFEDITAB CR | nifedipine | TABLET, EXTENDED RELEASE;ORAL | 075128-001 | Mar 10, 2000 | DISCN | No | No | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
